구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | nucleic acid sequencing (nucleic acid sequencing) University of Southern California·Unspecified Adult Solid Tumor, Pro… 33 trials |
|---|---|
Overview Program | nucleic acid sequencing |
Overview Company | University of Southern California |
Overview Modality | CGT |
Overview Target | Unspecified Adult Solid Tumor, Protocol |
Overview Indication | Unspecified Adult Solid Tumor, Protocol Specific |
Overview Phase | PHASE_1 |
Overview Status | ACTIVE |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Watch |
Overview Approval status | Investigational |
Toxicology Major finding | Pharmacokinetics and safety of a new free-base formulation of tenofovir alafenamide 25 mg in healthy volunteers: a randomized, open-label, four-period, fully replicated crossover bioequivalence study.. This study compared the pharmacokinetic bioequivalence and safety of a new free-base formulation of 25 mg tenofovir alafenamide (TAF) to those of a reference formulation under fasting cond… |
Clinical Safety signal | Pharmacokinetics and safety of a new free-base formulation of tenofovir alafenamide 25 mg in healthy volunteers: a randomized, open-label, four-period, fully replicated crossover bioequivalence study.. This study compared the pharmacokinetic bioequivalence and safety of a new free-base formulation of 25 mg tenofovir alafenamide (TAF) to those of a reference formulation under fasting cond… |
Clinical Selected reported efficacy | ORR 41.33% |
Clinical Reported ORR | 41.33% |
Clinical Result source | ClinicalTrials.gov NCT03486457 |
Clinical Program phase | PHASE_1 |
Clinical Trial ref | NCT03486457 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | nucleic acid sequencing (nucleic acid sequencing) University of Southern California·Unspecified Adult Solid Tumor, Pro… 33 trials |
|---|---|
Overview Program | nucleic acid sequencing |
Overview Company | University of Southern California |
Overview Modality | CGT |
Overview Target | Unspecified Adult Solid Tumor, Protocol |
Overview Indication | Unspecified Adult Solid Tumor, Protocol Specific |
Overview Phase | PHASE_1 |
Overview Status | ACTIVE |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Watch |
Overview Approval status | Investigational |
Toxicology Major finding | Pharmacokinetics and safety of a new free-base formulation of tenofovir alafenamide 25 mg in healthy volunteers: a randomized, open-label, four-period, fully replicated crossover bioequivalence study.. This study compared the pharmacokinetic bioequivalence and safety of a new free-base formulation of 25 mg tenofovir alafenamide (TAF) to those of a reference formulation under fasting cond… |
Clinical Safety signal | Pharmacokinetics and safety of a new free-base formulation of tenofovir alafenamide 25 mg in healthy volunteers: a randomized, open-label, four-period, fully replicated crossover bioequivalence study.. This study compared the pharmacokinetic bioequivalence and safety of a new free-base formulation of 25 mg tenofovir alafenamide (TAF) to those of a reference formulation under fasting cond… |
Clinical Selected reported efficacy | ORR 41.33% |
Clinical Reported ORR | 41.33% |
Clinical Result source | ClinicalTrials.gov NCT03486457 |
Clinical Program phase | PHASE_1 |
Clinical Trial ref | NCT03486457 |
추천 비교
추천 비교